At the heart of Ramage et al.’s study is the concept of co-production, which refers to the collaborative engagement of community members in the research process. This approach not only empowers individuals but also ensures that the interventions being tested are relevant to the communities they aim to serve. By involving members of ethnically diverse populations in the planning and execution of clinical trials, researchers are better positioned to address the unique barriers that these groups face. This mutual engagement fosters trust, a crucial element often lacking in traditional top-down research methodologies.

The authors emphasize that traditional clinical trials have often overlooked the specific needs and contexts of ethnically diverse communities, resulting in underrepresentation and skewed health outcomes. For instance, language barriers, cultural differences in health practices, and historical mistrust of medical institutions can significantly hinder participation rates. By involving community stakeholders from the outset, researchers can identify these barriers and develop strategies to mitigate them, creating a more inviting environment for potential participants.

A crucial aspect of facilitating participation revolves around the design and implementation of interventions that resonate with the target population. Ramage et al. argue that one-size-fits-all approaches are inherently flawed. Instead, interventions must be customized to reflect the cultural nuances and socio-economic realities of ethnically diverse communities. This requires not only input from local individuals but also ongoing dialogue to ensure that the research remains sensitive to changing dynamics within the community.

Moreover, co-production in clinical research serves as a bridge to enhance the validity of findings. When diverse communities are actively involved in the research process, the data collected can better represent the lived experiences of these populations. This increased representation will not only improve health outcomes during and after the trials but also inform broader public health policies, ultimately benefitting society at large.

Another critical dimension highlighted in the study is the importance of accessibility within the research framework. Accessibility extends beyond mere physical resources; it encompasses cognitive, linguistic, and emotional aspects as well. Trial protocols should be designed to ensure that participants can fully understand what their involvement entails, including potential risks and benefits. This entails providing materials in multiple languages and employing culturally competent staff to assist participants throughout the process.

Digital health tools are becoming increasingly prevalent in clinical research, offering promising avenues for enhancing engagement among ethnically diverse populations. Mobile applications and telehealth can provide innovative platforms for outreach, education, and ongoing support throughout the trial. However, researchers must remain vigilant about the digital divide that exists, ensuring that technology is not a barrier to participation.

Additionally, fostering long-term partnerships with local organizations can enhance community trust and facilitate recruitment. Ramage et al. underscore the role of grassroots groups that hold sway within ethnically diverse populations. These organizations can serve as vital conduits for information, outreach, and recruitment, enabling researchers to work alongside trusted figures within the community.

As researchers and stakeholders strive towards achieving equity in research, evaluating the effectiveness of co-produced interventions requires robust methodologies. Metrics must be developed not only to measure participation rates but also to assess the depth of engagement and satisfaction among participants. Such evaluations will be critical in refining intervention strategies and ensuring that future clinical trials benefit from the insights gained.

The implications of Ramage et al.’s study extend far beyond individual trials; they challenge the broader scientific community to rethink its approaches to diversity and inclusion. The movement towards more equitable research models has the potential to reshape how clinical trials are conducted across the globe. As researchers prioritize the voices of underrepresented populations, the likelihood of achieving comprehensive and equitable health solutions increases significantly.

The collaboration between researchers and communities marks a significant shift in how trials are conceptualized and implemented. By blending scientific expertise with community insights, the co-production model not only enhances the quality of research but also ensures that health advancements are accessible to everyone, irrespective of their ethnic background. This inclusive approach is anticipated to yield enhanced social justice outcomes in healthcare, paving the way for more equitable health systems.

Finally, the lessons drawn from co-produced interventions pave a pathway for future research endeavors. Moving forward, it is crucial for researchers to continually engage with diverse communities and adapt strategies based on real-time feedback. This iterative process embodies a commitment to inclusivity that extends beyond the scope of individual trials, forging stronger bonds between researchers and the communities they serve.

In conclusion, the study by Ramage et al. represents an essential contribution to the ongoing discourse surrounding equity and inclusion in clinical research. By emphasizing the significance of co-produced interventions, this research advances our understanding of how best to engage ethnically diverse populations in health research. As we move forward, it is imperative that the scientific community embraces these insights, ensuring that all communities are represented and valued in the quest for health equity.

Subject of Research: Co-production of interventions for clinical trials to enhance participation of ethnically diverse communities.

Article Title: Moving together to facilitate equity and inclusion in research.

Article References:

Ramage, E.R., Sharma, H., Batchelor, F. et al. Moving together to facilitate equity and inclusion in research. The co-production of interventions for clinical trials to facilitate participation of people from ethnically diverse communities.
Health Res Policy Sys 24, 9 (2026). https://doi.org/10.1186/s12961-025-01435-4

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12961-025-01435-4

Keywords: Co-production, clinical trials, ethnically diverse communities, health equity, inclusion, community engagement.

The persistent underrepresentation of socioeconomically disadvantaged groups in Alzheimer’s research has long hindered the generalizability and equity of clinical trial outcomes. Low-income individuals, particularly those reliant on Medicaid, often face systemic barriers that discourage their participation. These can include limited access to information, mistrust of medical institutions, and logistical difficulties. The USC study notably interrogates the contested ethical terrain around financial inducements in research recruitment. While such incentives have sparked debate over potential coercion or undue influence, the absence of consensus regarding their size and practical impact has left many recruiters cautious.

To tackle this recruitment challenge, the investigators designed a large-scale experiment targeting adults aged 50 and older, all receiving care through an integrated county health system primarily serving Medicaid enrollees. Nearly 50,000 individuals without a dementia diagnosis were invited via email or text message to join the Alzheimer Prevention Trials (APT) Webstudy, an influential platform aimed at accelerating clinical trials by earmarking higher-risk individuals for long-term monitoring. Participants were randomized into three distinct groups to compare the effectiveness of recruitment messaging and incentives.

The first group, termed the active control, received a baseline recruitment message that simply invited them to register in the memory concerns registry. The second group was offered a small yet tangible incentive: a $25 Amazon gift card contingent upon their enrollment. The third group experienced a different approach—entry into a prize drawing for a substantially larger $2,500 Amazon gift card, with odds set at 1 in 100. This structure allowed the researchers to evaluate not only whether incentives worked but also which type was most effective in motivating participation across diverse demographic segments.

The results were striking. The small guaranteed gift card incentive yielded nearly a 40% increase in enrollment compared to the control group, demonstrating that even modest financial rewards can substantially augment recruitment efforts among low-income older adults. A nuanced analysis revealed that the incentive was particularly effective for white males and Medicaid enrollees, populations historically underrepresented in clinical research. Interestingly, the lottery-style prize drawing did not produce any significant recruitment benefit, suggesting that the certainty of reward plays a more critical role in influencing participant behavior than the allure of larger but uncertain payoffs.

These findings challenge prevailing assumptions in clinical trial recruitment strategies, especially concerning cost-effectiveness. While the gift card incentive increased enrollment rates, the study observed that the baseline messaging without financial inducements remained a considerably cheaper method with a reasonable recruitment yield in absolute terms. This insight has profound implications for how research institutions allocate limited funds, particularly when balancing recruitment goals against budgetary constraints.

The study authors argue that investing in targeted outreach efforts, educational programs, and structural supports for underrepresented communities might ultimately be a more sustainable and ethically sound approach than relying solely on financial incentives. Outreach initiatives that build trust and reduce systemic barriers could complement the recruitment process, thereby fostering genuine engagement and retention in registries and trials over the long term.

Conducted through the Alzheimer’s Trial Recruitment Innovation Lab (ATRIL)—a synergistic collaboration between the USC Schaeffer Center, the Alzheimer’s Therapeutic Research Institute (ATRI), and Howard University—this research embodies a multidimensional effort to revitalize diversity in Alzheimer’s clinical research. Funded principally by the American Heart Association, ATRIL exemplifies how cross-institutional partnerships can mobilize resources and expertise to tackle entrenched inequities in clinical trial participation.

The lead investigators, Mireille Jacobson and Doris Molina-Henry, bring complementary expertise from gerontology, neuropsychology, and neurology, enabling a comprehensive approach to trial design and participant engagement. Their work, published on August 22, 2025, in JAMA Health Forum, contributes not only empirical data on incentive efficacy but also a valuable ethical discussion on the delicate balance between compelling participation and respecting autonomy.

The research further situates itself within a broader landscape of ongoing debates regarding medical ethics in clinical trial recruitment. Financial incentives, though controversial, if structured responsibly, may act as facilitators of equity rather than coercion. However, the absence of a positive effect from larger, lottery-based rewards tempers enthusiasm for “carrot-and-stick” tactics that rely purely on economic enticement without mitigating other participation barriers.

On a methodological level, the study’s rigorous randomized controlled design provides robust evidence, minimizing biases that may have plagued prior observational or anecdotal investigations. Randomization ensured equitable distribution of sociodemographic factors, enabling confident attribution of observed recruitment differences to the incentive interventions themselves rather than confounding variables. This strengthens the case for practical application of such incentives in real-world trial recruitment.

Moreover, by focusing on a memory concerns registry rather than a direct clinical trial, the study recognized the foundational importance of early-stage engagement and tracking. Registries serve as critical reservoirs of eligible participants, streamlining recruitment pipelines for subsequent interventions and observational studies. Enhancing their diversity amplifies the translational impact of Alzheimer’s research, increasing the external validity of findings and facilitating development of treatments that are effective across population strata.

Despite its promising insights, the study also underscores that financial incentives constitute only one piece in a complex puzzle of clinical trial engagement. The interplay between socioeconomic status, race, gender, health literacy, and institutional trust necessitates multifaceted intervention strategies. Future efforts might integrate incentive programs with culturally tailored communication, community partnership models, and technological innovations to create an ecosystem conducive to inclusive research participation.

In summary, the USC-led investigation delivers compelling evidence that modest financial incentives can notably improve enrollment rates of low-income older adults in Alzheimer’s disease registries without ethical compromise or excessive cost. It simultaneously critiques the allure of large-prize lotteries, emphasizing the importance of predictable rewards and thoughtful resource allocation. Their findings pave the way for reimagining recruitment paradigms that, combined with community engagement and systemic reforms, hold promise for accelerating Alzheimer’s research while ensuring equity and representativeness.

Subject of Research: Recruitment strategies to increase diversity of older adults in Alzheimer’s disease patient registries through financial incentives.

Article Title: Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry

News Publication Date: 22-Aug-2025

Web References:
https://www.alzheimers.gov/clinical-trials/alzheimer-prevention-trials-apt-webstudy
https://schaeffer.usc.edu/people/mireille-jacobson-phd/
https://schaeffer.usc.edu/people/doris-molina-henry-phd/
https://schaeffer.usc.edu/clinical-trial-recruitment-lab/alzheimers-trial-recruitment-innovation-lab/

References: Jacobson M, Molina-Henry D, et al. Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry. JAMA Health Forum. 2025; DOI:10.1001/jamahealthforum.2025.2273.

Keywords: Alzheimer disease, Clinical trials, Medical ethics, Dementia, Medical economics, Geriatrics